These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29146159)

  • 1. A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib.
    Chen Y; Chen B; Zhu X; Zhong J
    Lung Cancer; 2018 Feb; 116():96-98. PubMed ID: 29146159
    [No Abstract]   [Full Text] [Related]  

  • 2. A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib.
    Zhu YC; Wang WX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y
    Clin Lung Cancer; 2019 May; 20(3):e224-e228. PubMed ID: 30914311
    [No Abstract]   [Full Text] [Related]  

  • 3. Arginine deprivation for ASS1-deficient mesothelioma.
    Burki TK
    Lancet Oncol; 2016 Oct; 17(10):e423. PubMed ID: 27622996
    [No Abstract]   [Full Text] [Related]  

  • 4. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
    Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
    Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
    Bronte G; Incorvaia L; Rizzo S; Passiglia F; Galvano A; Rizzo F; Rolfo C; Fanale D; Listì A; Natoli C; Bazan V; Russo A
    Crit Rev Oncol Hematol; 2016 Nov; 107():20-32. PubMed ID: 27823648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
    Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
    Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.
    Petri GL; Cascioferro S; Parrino B; Peters GJ; Diana P; Giovannetti E
    Pharmacogenomics; 2018 Jul; 19(10):811-814. PubMed ID: 29916298
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer.
    Lucchesi C; Drogat B; Santamaria D; Cousin S; Italiano A
    Lung Cancer; 2018 Dec; 126():227-229. PubMed ID: 30342857
    [No Abstract]   [Full Text] [Related]  

  • 10. The therapeutic implications of the genomic analysis of malignant pleural mesothelioma.
    Zauderer MG
    Nat Commun; 2021 Mar; 12(1):1819. PubMed ID: 33753750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma.
    Baird AM; Finn SP; Gray SG; Sheils O
    J Thorac Oncol; 2021 Jan; 16(1):14-16. PubMed ID: 33384056
    [No Abstract]   [Full Text] [Related]  

  • 12. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
    Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
    Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF
    Falcone R; Conte F; Fiscon G; Pecce V; Sponziello M; Durante C; Farina L; Filetti S; Paci P; Verrienti A
    Endocrine; 2019 May; 64(2):406-413. PubMed ID: 30850937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
    Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
    Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of epigenetics in malignant pleural mesothelioma.
    Vandermeers F; Neelature Sriramareddy S; Costa C; Hubaux R; Cosse JP; Willems L
    Lung Cancer; 2013 Sep; 81(3):311-318. PubMed ID: 23790315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
    Gautschi O; Peters S; Zoete V; Aebersold-Keller F; Strobel K; Schwizer B; Hirschmann A; Michielin O; Diebold J
    Lung Cancer; 2013 Nov; 82(2):365-7. PubMed ID: 24035431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.
    El Karak F; Assi T; Kourie HR; El Rassy E; Chebib R; Ghor M; Tabchi S
    Int J Clin Exp Pathol; 2015; 8(3):3294-8. PubMed ID: 26045855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.
    Kaku Y; Nagaya H; Tsuchiya A; Kanno T; Gotoh A; Tanaka A; Shimizu T; Nakao S; Tabata C; Nakano T; Nishizaki T
    Cancer Sci; 2014 Jul; 105(7):883-9. PubMed ID: 24754309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF V600E Mutation in Involuting Nevus in a Patient Treated With Vemurafenib.
    Millán-Cayetano JF; Fernández-Canedo I; Blázquez-Sánchez N; Fúnez-Liébana R; de Troya-Martín M
    JAMA Dermatol; 2017 Jun; 153(6):605-607. PubMed ID: 28249088
    [No Abstract]   [Full Text] [Related]  

  • 20. Is There Room for Second-Line Treatment of Pleural Malignant Mesothelioma?
    Addeo A; Buffoni L; Di Maio M
    JAMA Oncol; 2017 Sep; 3(9):1170-1171. PubMed ID: 28114625
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.